Patient's Derived Organoids for Drug Screening in Glioblastoma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
About this trial
The study will enroll patients suffering from glioblastoma, a malignant brain tumor. Intervention is intended as a laboratory intervention and not as a clinical intervention. In fact, tumor removed from patients' brains will be sent to a dedicated laboratory to obtain an "avatar" of the tumor, named patient-derived organoid (PDO). A number of experimental antitumor approaches will be studied on PDOs. Results of these experiments will be correlated to the prognosis of patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
adult patients undergoing resective neurosurgery for glioblastoma, IDH-wildtype
Disqualifiers
Needle biopsies
Age <18 years
Inability to give informed consent
Brain surgery for tumor disease other than GBM
Trial design
Design model
Single group
Treatments tested in this trial
Development and characterization of PDOs
Biological/VaccineAn amount of tissue of approximately 2-3 cm3, if available, will be allocated to the study. The specimen will be divided in three parts (depending on the volume of the biopsy) and used to: a) obtain PDOs according to established procedures (Chadwick, et al., 2020; Gamboa, et al., 2021); b) flash-frozen for molecular analysis of original tissue; c) used to isolate GSCs by flow-cytometry cell sorting. Only PDOs characterized by histological and molecular conformity with primary tumors will be used. The mutational status of genes frequently associated with GBM onset and progression will be analyzed in PDOs, and compared with data derived from tumor DNA, in order to assess their representation of the genetic heterogeneity of original tumors. These studies will allow us the set up a reliable procedure for the ex-vivo establishment of pre-clinical models of GBM.
Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs
Biological/VaccinePDOs and GSCs representing different GBM molecular subtypes will be treated with epigenetic modulators , with spliceosome inhibitors or with drugs that indirectly target the splicing machinery, such as PRMT5 inhibitors. These drugs will be tested for their ability to suppress growth and/or induce cell death, when administered either alone or in combination with standard chemotherapy. Furthermore, the investigators will perform RNA sequencing experiments to identify TE-derived transcripts and splice variants induced by the treatments. By employing a computational pipeline developed in our laboratory (Pieraccioli and Sette, unpublished), the investigators will also characterize the affinity for MHC-I and immunogenicity of neoepitopes encoded by the treatment-induced TE-derived transcripts and splice variants. The results of these analysis will allow to identify neoepitopes to be used for designing immunotherapy approaches.
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: PDO armExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Histopathological PDO and tumor evaluation
The histopathological resemblance of PDOs to primary tumor will be rated semiquantitatively (0-10). The efficacy of treatment on PDOs will be rated using the % of dead cells.
Time frame
From enrollment to 36 monthsSecondary outcomes
1
Histopatological primary and recurrent PDO evaluation.
Histological resemblance of PDOs generated from primary and recurrent tumor will be rated semiquantitatively (0-10).
Time frame
From enrollment to 36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: